These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24518133)

  • 1. Liquid chromatography-tandem mass spectrometric assay for the light sensitive survivin suppressant sepantronium bromide (YM155) in mouse plasma.
    Dolman ME; den Hartog IJ; Molenaar JJ; Schellens JH; Beijnen JH; Sparidans RW
    J Pharm Biomed Anal; 2014 Apr; 92():144-8. PubMed ID: 24518133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma.
    Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Apr; 925():124-8. PubMed ID: 23537694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liquid chromatography-tandem mass spectrometric assay for the cyclin-dependent kinase inhibitor AT7519 in mouse plasma.
    Dolman ME; den Hartog IJ; Molenaar JJ; Schellens JH; Beijnen JH; Sparidans RW
    J Pharm Biomed Anal; 2014 Jan; 88():216-20. PubMed ID: 24080524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid chromatography-tandem mass spectrometric assay for the PI3K/mTOR inhibitor GSK2126458 in mouse plasma and tumor homogenate.
    Dolman ME; Westerhout EM; Hamdi M; Schellens JH; Beijnen JH; Sparidans RW
    J Pharm Biomed Anal; 2015 Mar; 107():403-8. PubMed ID: 25659532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.
    Sparidans RW; Tang SC; Nguyen LN; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():150-4. PubMed ID: 22940474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction.
    Sparidans RW; van Hoppe S; Rood JJ; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Feb; 1012-1013():118-23. PubMed ID: 26826475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
    Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():174-7. PubMed ID: 22476054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liquid chromatography-electrospray tandem mass spectrometric assay suitable for quantitation of YM155, a novel small-molecule survivin suppressant, in dog plasma.
    Minematsu T; Felder L; Oppeneer T; Sakazume M; Oikawa K; Hashimoto T; Usui T; Kamimura H
    Biomed Chromatogr; 2008 Jul; 22(7):763-9. PubMed ID: 18348340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor efficacy and biodistribution of liposomal sepantronium bromide (YM155), a novel small-molecule survivin suppressant.
    Kawano H; Shakushiro K; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
    Eur J Pharm Biopharm; 2014 Sep; 88(1):283-9. PubMed ID: 24993306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma.
    Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
    J Pharm Biomed Anal; 2014 Jan; 88():626-9. PubMed ID: 24216281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma.
    Sparidans RW; Kort A; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jun; 1023-1024():24-9. PubMed ID: 27179188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.
    Sparidans RW; Iusuf D; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(32):4090-6. PubMed ID: 19910267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
    Sparidans RW; Durmus S; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Mar; 889-890():144-7. PubMed ID: 22386128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.
    Luethi D; Durmus S; Schinkel AH; Schellens JH; Beijnen JH; Sparidans RW
    Biomed Chromatogr; 2014 Oct; 28(10):1366-70. PubMed ID: 24619951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting response to sepantronium bromide (YM155), a survivin suppressant, by PET imaging with [
    Mitsuoka K; Kita A; Murakami Y; Shirasuna K; Noda A; Yamanaka K; Kaneko N; Miyoshi S
    Nucl Med Biol; 2018; 64-65():41-46. PubMed ID: 30041149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates.
    Sparidans RW; Iusuf D; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Oct; 878(28):2751-9. PubMed ID: 20829130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.
    Sparidans RW; Ahmed TT; Muilwijk EW; Welzen ME; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Sep; 905():137-40. PubMed ID: 22917595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formulation design and evaluation of liposomal sepantronium bromide (YM155), a small-molecule survivin suppressant, based on pharmacokinetic modeling and simulation.
    Shakushiro K; Kawano H; Nakata M; Kita A; Maeda A; Watanabe S; Sako K; Oku N
    Pharm Res; 2015 Jan; 32(1):238-47. PubMed ID: 25033765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.
    Sparidans RW; Durmus S; Xu N; Schinkel AH; Schellens JH; Beijnen JH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 May; 895-896():169-73. PubMed ID: 22476055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid chromatography-tandem mass spectrometry assay for therapeutic drug monitoring of the tyrosine kinase inhibitor, midostaurin, in plasma from patients with advanced systemic mastocytosis.
    Bourget P; Amin A; Chandesris MO; Vidal F; Merlette C; Hirsch I; Cabaret L; Carvalhosa A; Mogenet A; Frenzel L; Damaj G; Lortholary O; Hermine O
    J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 944():175-81. PubMed ID: 24316764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.